[Activity of anidulafungin against Candida biofilms].

Surface functionalization by covalent immobilization of an innovative carvacrol derivative to avoid fungal biofilm formation. AMB Express (2015) 1.39

Characterization of Candida parapsilosis complex strains isolated from invasive fungal infections. Eur J Clin Microbiol Infect Dis (2011) 0.79

The Role of Antifungals against Candida Biofilm in Catheter-Related Candidemia. Antibiotics (Basel) (2014) 0.75

Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J Clin Microbiol (2004) 4.70

Antifungal drug resistance mechanisms. Expert Rev Anti Infect Ther (2009) 1.68

Epidemiology, species distribution and in vitro antifungal susceptibility of fungaemia in a Spanish multicentre prospective survey. J Antimicrob Chemother (2012) 1.31

Comparison of the Sensititre YeastOne colorimetric antifungal panel and Etest with the NCCLS M38-A method to determine the activity of amphotericin B and itraconazole against clinical isolates of Aspergillus spp. J Antimicrob Chemother (2003) 1.11

A positional scanning combinatorial library of peptoids as a source of biological active molecules: identification of antimicrobials. J Comb Chem (2003) 0.92

[Epidemiology of candidemia in Spain - Multicenter study] Rev Iberoam Micol (2002) 0.92

Differentiation of Candida parapsilosis, C. orthopsilosis, and C. metapsilosis by specific PCR amplification of the RPS0 intron. Int J Med Microbiol (2011) 0.90

In vitro activities of echinocandins against Candida krusei determined by three methods: MIC and minimal fungicidal concentration measurements and time-kill studies. Antimicrob Agents Chemother (2009) 0.90

Fungemia due to Candida guilliermondii in a pediatric and adult population during a 12-year period. Diagn Microbiol Infect Dis (2007) 0.88

Comparison of in vitro antifungal activities of amphotericin B lipid complex with itraconazole against 708 clinical yeast isolates and opportunistic moulds determined by National Committee for Clinical Laboratory Standards methods M27-A and M38-P. Chemotherapy (2002) 0.86

Voriconazole in the management of nosocomial invasive fungal infections. Ther Clin Risk Manag (2006) 0.86

Comparison of micafungin MICs as determined by the Clinical and Laboratory Standards Institute broth microdilution method (M27-A3 document) and Etest for Candida spp. isolates. Diagn Microbiol Infect Dis (2011) 0.84

[Changes in the epidemiology of fungaemia and fluconazole susceptibility of blood isolates during the last 10 years in Spain: results from the FUNGEMYCA study]. Rev Iberoam Micol (2011) 0.84

Comparison of posaconazole and voriconazole in vitro killing against Candida krusei. Diagn Microbiol Infect Dis (2008) 0.83

Spondylodiscitis caused by Candida krusei: case report and susceptibility patterns. J Clin Microbiol (2006) 0.82

Epidemiology and antifungal susceptibility of bloodstream fungal isolates in pediatric patients: a Spanish multicenter prospective survey. J Clin Microbiol (2011) 0.81

[Native valve Aspergillus fumigatus endocarditis with blood culture positive and negative for galactomannan antigen. Case report and literature review]. Rev Iberoam Micol (2007) 0.80

In vitro activity of echinocandins against non-Candida albicans: is echinocandin antifungal activity the same? Enferm Infecc Microbiol Clin (2011) 0.79

Multidisciplinary approach to the treatment of invasive fungal infections in adult patients. Prophylaxis, empirical, preemptive or targeted therapy, which is the best in the different hosts? Ther Clin Risk Manag (2008) 0.79

[Age group, geographical incidence and patterns of antifungal susceptibility of Candida species causing candidemia in the Spanish paediatric population]. Enferm Infecc Microbiol Clin (2013) 0.78

[In vitro activity of amphotericin B and anidulafungin against Candida spp. biofilms]. Rev Iberoam Micol (2007) 0.78

[In vitro antifungal activity of micafungin]. Rev Iberoam Micol (2009) 0.78

Evaluation of disk diffusion method compared to broth microdilution for antifungal susceptibility testing of 3 echinocandins against Aspergillus spp. Diagn Microbiol Infect Dis (2012) 0.76

[In vitro antifungal activity of voriconazole: New data after the first years of clinical experience]. Rev Iberoam Micol (2007) 0.75

Activity-bioavailability balance in oral drug development for a selected group of 6-fluoroquinolones. J Pharm Sci (2002) 0.75